Suppr超能文献

使用美敦力MiniMed™ 780G系统进行膳食管理的叙述性综述:1型糖尿病膳食管理的演变

A narrative review of meal management with the MiniMed™ 780G system: Evolution of dietary management in type 1 diabetes.

作者信息

Edd Shannon, Laron-Hirsch Maya, Castañeda Javier, van den Heuvel Tim, Petrovski Goran, Cohen Ohad

机构信息

Medtronic International Trading Sarl, Tolochenaz, Switzerland.

Sheba Medical Center, Tel Aviv, Israel.

出版信息

Diabetes Obes Metab. 2026 Jan;28 Suppl 1(Suppl 1):61-68. doi: 10.1111/dom.70310. Epub 2025 Nov 28.

Abstract

BACKGROUND

Type 1 diabetes (T1D) meal management has long relied on structured carbohydrate counting and rigid bolus timing to achieve optimal glycaemic outcomes. However, these strategies impose a cognitive burden and are difficult to sustain in daily life. This narrative review evaluates how the MiniMed™ 780G Automated Insulin Delivery (AID) system enables revisiting management strategies with simplified and flexible approaches without significantly compromising clinical efficacy.

METHODS

A narrative review was conducted based on published clinical studies and real-world evidence (RWE) papers collected from MiniMed™ 780G system users. The analysis focused on meal bolusing patterns, unannounced meals, carbohydrate counting strategies, high-fat/high-protein diets, fasting regimens, and other meal-related conditions.

RESULTS

Evidence suggests that the MiniMed™ 780G system provides significant flexibility in meal management without compromising glycaemic outcomes. Comparable time in range (TIR) was observed whether insulin was bolused pre-meal or at meal start, although delaying bolusing beyond 30 min post-meal led to greater glucose excursions. The system demonstrated the capability to compensate for missed meal boluses of up to 30 g of carbohydrates. Predefined fixed meal bolusing strategies may be more convenient for people with diabetes who are hesitant to perform precise carbohydrate counting, yet they can still achieve international glycaemic targets. Additionally, the system effectively adapts to high-fat, high-protein meals and fasting regimens, such as those observed during Ramadan, with minimal impact on TIR. Real-world data from over 61 000 users confirm that adherence to the system's optimal settings (glucose target of 100 mg/dL, active insulin time 2 h) and the use of 2-3 carbohydrate ratios per day resulted in the greatest glycaemic benefit.

CONCLUSION

The MiniMed™ 780G system shifts the paradigm of meal management in T1D from intensive self-regulation toward automation and behavioral sustainability. These findings support broader access to AID technology by reducing reliance on precise carb counting and aligning therapy with real-world needs.

摘要

背景

1型糖尿病(T1D)的膳食管理长期以来一直依赖于结构化的碳水化合物计数和严格的大剂量胰岛素注射时间,以实现最佳血糖结果。然而,这些策略带来了认知负担,且在日常生活中难以维持。本叙述性综述评估了美敦力780G自动胰岛素输送(AID)系统如何能够通过简化和灵活的方法重新审视管理策略,而不会显著影响临床疗效。

方法

基于已发表的临床研究以及从美敦力780G系统用户收集的真实世界证据(RWE)论文进行叙述性综述。分析重点关注进餐时的大剂量胰岛素注射模式、未提前通知的进餐、碳水化合物计数策略、高脂肪/高蛋白饮食、禁食方案以及其他与进餐相关的情况。

结果

有证据表明,美敦力780G系统在膳食管理方面提供了显著的灵活性,且不影响血糖结果。无论胰岛素是在餐前还是进餐开始时注射,观察到的血糖范围内时间(TIR)相当,尽管在餐后30分钟后延迟注射会导致更大的血糖波动。该系统显示出能够补偿高达30克碳水化合物的漏餐大剂量胰岛素注射。预定义的固定进餐大剂量胰岛素注射策略对于那些对精确碳水化合物计数犹豫不决的糖尿病患者可能更方便,但他们仍然可以实现国际血糖目标。此外,该系统能有效适应高脂肪、高蛋白饮食以及禁食方案,如斋月期间观察到的情况,对TIR的影响最小。来自超过61000名用户的真实世界数据证实,遵循该系统的最佳设置(血糖目标为100mg/dL,活性胰岛素时间为2小时)以及每天使用2 - 3种碳水化合物比例可带来最大的血糖益处。

结论

美敦力780G系统将T1D的膳食管理模式从强化自我调节转变为自动化和行为可持续性。这些发现通过减少对精确碳水化合物计数的依赖以及使治疗与现实需求相匹配,支持更广泛地使用AID技术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c12/12805926/fe4cb43489b2/DOM-28-61-g001.jpg

相似文献

本文引用的文献

7
Dietary treatment of type 1 diabetes - once upon a time versus today.1 型糖尿病的饮食治疗——过去与现在。
Pediatr Endocrinol Diabetes Metab. 2023;29(3):184-189. doi: 10.5114/pedm.2023.132027.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验